This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

5 Stock Insiders are Gobbling Up

AVEO Pharmaceuticals has a market cap of $296 million and an enterprise value of $144 million. This stock trades at a premium valuation, with a price-to-sales of 63.55 and a price-to-book of 2.23. Its estimated growth rate for this year is -493.2%, and for next year it's pegged at 29.2%. This is a cash-rich company, since the total cash position on its balance sheet is $189.69 million and its total debt is $25.96 million.

The CEO just bought 75,000 shares, or about $498,000 worth of stock, at $6.61 to $6.85 per share. A director also just bought 15,000 shares, or about $101,000 worth of stock, at $6.65 per share.

From a technical perspective, AVEO is currently trending below both its 50-day and 200-day moving averages, which is bearish. This stock recently formed a double bottom chart pattern at $5.80 to $5.95 a share. Following that bottom, shares of AVEO have started to rebound back towards its 50-day moving average of $7.20 a share.

If you're in the bull camp on AVEO, then I would look for long-biased if this stock manages to break out above some near-term overhead resistance levels at $7.20 to $7.32 share with high volume. Look for a sustained move or close above those levels with volume that registers near or above its three-month average action of 322,719 shares. If that breakout triggers soon, then AVEO will set up to re-test or possibly take out its next major overhead resistance levels at $7.82 to $8.25 a share. Any high-volume move above $8.25 to $8.50 will then put $10 a share into focus for shares of AVEO.


One name in the healthcare complex that insiders are jumping into here is Akorn (AKRX). This company manufactures and markets a full line of diagnostic and therapeutic ophthalmic pharmaceuticals as well as niche hospital drugs and injectable pharmaceuticals. Insiders are buying this stock into some notable strength, since shares are up 20% so far in 2012.

Akorn has a market cap of $1.28 billion and an enterprise value of $1.33 billion. This stock trades at a fair valuation, with a trailing price-to-earnings of 46.06 and a forward price-to-earnings of 20.38. Its estimated growth rate for this year is 45.7%, and for next year it's pegged at 29.4%. This is not a cash-rich company, since the total cash position on its balance sheet is $38.4 million and its total debt is $103.65 million.

3 of 6

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,265.99 +109.14 0.64%
S&P 500 2,011.36 +9.79 0.49%
NASDAQ 4,593.4250 +31.2360 0.68%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs